Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tarix Pharmaceuticals has recruited first patient in a double-blind, placebo-controlled multi-center Phase 2 trial investigating TXA127 in the acceleration of engraftment following autologous peripheral blood stem cell transplant in patients with Hodgkin or non-Hodgkin lymphomas or multiple myeloma undergoing limited reinfusion of CD34+ cells.
Subscribe to our email newsletter
TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.
Tarix Pharma expects to recruit a total of 74 patients at eight US medical centers.
The company has received US Food and Drug Administration (FDA) approval as a treatment to enhance engraftment in patients receiving a stem cell transplant.
Tarix Pharma CEO Rick Franklin said TXA127 has the potential to reduce the time it takes for blood cell counts to return to safe levels following stem cell transplant, which may accelerate the recovery process and reduce some of the health risks associated with stem cell transplant.
"TXA127 is unique because it directly stimulates transplanted stem cells to replenish circulating platelets, white blood cells, and red blood cells," Franklin said.